{"groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023.","id":"FG000","title":"Multiple Myeloma/Blenrep Participants"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"comment":"Completed is defined as having contributed data during the study period.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"57 Duke patients were identified with RRMM who began treatment with Blenrep between Aug 5, 2020 and Nov 22, 2022. 25 patients were excluded (9 concurrently receiving other therapies, 8 being followed by a local oncologist or without Blenrep Risk Evaluation and Mitigation Strategies \\[REMS\\] documentation, 5 with \\<1 mo. of follow-up, and 3 receiving Blenrep as part of an expanded access pathway). Of the 32 remaining patients, 30 patients were randomly selected for chart abstraction.","recruitmentDetails":"This was a single-site, retrospective, observational study examining longitudinal care patterns for belantamab mafodotin among relapsed and/or refractory multiple myeloma (RRMM) patients seen at Duke Cancer Institute (DCI)."}